The review also addresses donor selection (sex, age, HLA disparity, and ABO blood type), donor source, the dose of infused CD34+ cells, optimal conditioning, and the concomitant GVHD prophylaxis other than PTCY. The gene discussed is ABO; the disease is graft versus host disease.